Compare AIHS & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | AIHS | PPCB |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | China | Australia |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 5.7M |
| IPO Year | 2018 | N/A |
| Metric | AIHS | PPCB |
|---|---|---|
| Price | $1.17 | $0.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 30.8K | ★ 270.0K |
| Earning Date | 02-13-2026 | 02-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,560,626.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.83 | $0.24 |
| 52 Week High | $17.00 | $145.46 |
| Indicator | AIHS | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 48.65 | 22.64 |
| Support Level | $1.15 | $0.24 |
| Resistance Level | $1.41 | $0.34 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 35.90 | 18.88 |
Senmiao Technology Ltd is a holding company. Along with its subsidiaries, it is engaged in facilitating automobile transactions and offering related services. The group's business activities include providing car rental services to individual customers with lease term no more than twelve months; leasing and servicing of new energy vehicles; offering services to automobile purchasers throughout the purchase process; providing management and related services to Partner Platforms and other companies; automobile financing; and providing other related supporting services to customers. The majority of the group's revenue is generated from its automobile rental business.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.